Genset delays Famoxin clinical trials

Genset (GENXY; NM:Genset) delayed the start of Phase I testing of its Famoxin protein fragment to treat obesity to the first half of 2002 from the end of this year. The company said the delay is related to the production of Famoxin, a cleavage product of the Acrp30 hormone secreted by fat cells, which "was more difficult than expected because of very different and unexpected solubility properties" from those of the mouse protein. GENXY added that it now has isolated and produced the human fragment. GENXY was off $0.31 (14%) to $1.94 on Monday, and was off 27% the prior week. ...